Jim Simons Cabaletta Bio, Inc. Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$16.79 - $25.38 $990,610 - $1.5 Million	59,000 New	59,000 $1.01 Million
Q2 2023 Aug 11, 2023	SELL	$7.65 - $13.95 $268,515 - $489,645	-35,100 Reduced 31.12%	77,700 $1 Million
Q1 2023 May 12, 2023	SELL	$7.08 - $12.62 $358,248 - $638,572	-50,600 Reduced 30.97%	112,800 $933,000
Q4 2022 Feb 13, 2023	SELL	$0.64 - $9.3 $335,399 - $4.87 Million	-524,061 Reduced 76.23%	163,400 $1.51 Million
Q3 2022 Nov 14, 2022	BUY	$0.63 - $2.05 $222,050 - $722,545	352,461 Added 105.21%	687,461 $447,000
Q2 2022 Aug 12, 2022	BUY	$0.99 - $2.11 $134,244 - $286,116	135,600 Added 68.0%	335,000 $355,000
Q1 2022 May 13, 2022	BUY	$1.68 - $3.92 $334,992 - $781,648	199,400 New	199,400 $405,000
Q3 2021 Nov 12, 2021	SELL	$7.0 - $12.5 $104,300 - $186,250	-14,900 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$7.2 - $11.73 $107,280 - $174,777	14,900 New	14,900 $128,000
Q3 2020 Nov 13, 2020	SELL	$9.71 - $14.41 $596,650 - $885,451	-61,447 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$6.39 - $11.28 $309,576 - $546,482	48,447 Added 372.67%	61,447 $685,000
Q1 2020 May 14, 2020	BUY	$6.0 - $18.67 $78,000 - $242,710	13,000 New	13,000 $95,000

126

47.9M

202K

110K

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $66.4M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.